|
|
 |
|
Viewing report
|
|
|
|
The North America Biotechnology Sectors : A Company and Industry Analysis (February 2007)
Mergent, Feb 2007, Pages: 36
This report looks at the biotechnology industry in the United States and Canada
Current Environment - Key Points
- Biotech had an improved final quarter in 2006 compared to the third quarter
The NASDAQ Biotech Index was up by nearly 7% over the six months to the end of the year
The Amex Biotech Index grew 12.8% over the same period
- The Canadian biotech sector, which faltered in the second quarter of 2006, continued to decline in the third quarter but rebounded in October and November as falling oil prices pushed stocks higher
- There was a surge in the values of biotech buyouts over the past six months
A Mergent analysis showed that in the second half of 2006, there were about 17 biotech M&As in the US worth an estimated US$8.80 billion
The amount was more than double the US$3.3 billion recorded by 32 companies in the first half
- In the second half of 2006 the Canadian biotech sector saw six biotech M&As, with a total value of US$624.5 million
- In the US, five biotech companies completed their IPOs in the second half of 2006
The US$299.5 million raised from IPOs was down 29% from the US$423.3 million raised in the first half of 2006
Only one biotech company managed to get listed in Canada in the second half of 2006
Industry Profile - Key Points
- In 2006, industrial biotech was given a boost in the US, mainly due to breakthroughs in the production of bioethanol and President Bush's Advanced Energy Initiative (AEI)
- On December 12, 2006, the Senate passed legislation that aims to help create cellulosic biomass ethanol plants
- The Securities and Exchange Commission (SEC) announced plans to ease auditing standards for small, publicly traded companies
- In the US, the biotech sector enjoyed greater finance levels over the past six months
A Mergent Analysis showed that in the second half of 2006, 35 biotech companies raised US$1,018 million in venture capital
- In October 2006, the Canadian Biotechnology Advisory Committee (CBAC) published a report in an effort to review the existing Canadian Biotechnology Strategy
- In December 2006, the Canadian Federal Government announced regulations to require 5% renewable content in gasoline by 2010 and a 2% renewable content in diesel and home heating fuel by no later than 2012
Market Trends and Outlook - Key Points
- With some biologic drugs costing up to US$100,000 a year for rare disorders, generics offer lower costs
Currently, no regulatory mechanism exists in the US to approve substitute versions of biotech drugs
Democrat control of Congress is expected to lead to legislation allowing generic versions of popular biotech drugs
- A survey by strategic management and technology consulting firm Booz Allen Hamilton of top global companies found that three quarters of R&D sites planned in 2007 will go to India and China
- Organizations, institutes and regulators around the world are increasingly forming international links as a way to strengthen their biotech industries
- On December 6, 2006, the National Research Council of Canada signed a Memorandum of Understanding (MOU) with the Government of India to extend scientific collaboration in the field of biotech
Customers who bought this item also bought
The North America Biotechnology Sectors : A Company and Industry Analysis (August 2007)
North America Biotechnology Sectors : A Company and Industry Analysis (February 2008)
Biotech 2009-Life Sciences: Navigating the Sea Change
US Biotech Market Analysis
The North America Biotechnology Sectors : A Company and Industry Analysis (August 2006)
Global Biotech Industry Monitor
Biotech Life Sciences: A 20/20 Vision to 2020
The North America Biotechnology Sectors : A Company and Industry Analysis (February 2006)
Understanding the Global Biotech Industry
China Biotech 2008
Booming Biotech Market in India
The North America Biotechnology Sectors : A Company and Industry Analysis (September 2004)
|
|
|
|
